Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate for multiple sclerosis (MS). The deal works out at $40 million upfront and there is a further $765 million lying in-wait for Principia, dependent upon milestone payments.

 

Bron: Pharmafile | lees verder..